<DOC>
	<DOCNO>NCT02679014</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , two treatment , parallel group study investigate effect RG7625 , cathepsin S inhibitor , immune response gluten challenge volunteer celiac disease . Volunteers previously diagnose celiac disease randomize receive either 100 milligram ( mg ) RG7625 placebo twice daily food 28 day ( Days 1 28 ) .</brief_summary>
	<brief_title>A Study Investigate Pharmacokinetics , Pharmacodynamic Effects , Safety Tolerability Repeated Dosing RG7625 Volunteers With Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Volunteers biopsy confirm diagnosis celiac disease Human leukocyte antigen ( HLA ) serotype DQ 2.5 HLADQ 8 haplotype Maintaining glutenfree diet least one year . Compliance assess serology , compatible response selfreported assessment glutenfree diet adherence absence typical celiac disease symptom Able participate comply study restriction include requirement gluten challenge A diagnosis nonceliac gluten sensitivity A personal history food intolerance gluten , diagnosis galactosemia , lactose , galactose fructose intolerance A personal history severe acute symptomatic reaction sporadic gluten ingestion A diagnosis refractory celiac disease presence severe complication celiac disease Diagnosed suspect immunoglobulin A ( IgA ) deficiency Acute inflammatory bowel disease ( ulcerative colitis , Crohn 's disease ) , gastrointestinal obstruction subocclusive syndrome , digestive perforation risk digestive perforation , painful abdominal syndrome undetermined cause A history stomach intestinal surgery resection . Appendectomy hernia repair acceptable Any confirm significant allergic reaction ( urticaria anaphylaxis ) drug , multiple allergy ( nonactive hay fever acceptable ) Immunocompromised reduce immune function consider clinically significant Investigator Immunization within 30 day screen visit planning vaccination study Women pregnant lactating , childbearing potential agree comply requirement contraceptive use . Men agree comply requirement contraceptive use restriction sperm donation Participation investigational drug device study within three month precede screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>